Clinical Trials
The Clinical Research Institute of Ohio (CRIOH) in Westlake, OH, conducts late-phase clinical trials dedicated to improving treatments for liver disease, obesity, and metabolic disorders. Our research brings promising therapies to patients in our region, offering access to cutting-edge options for conditions such as MASLD, MASH, cirrhosis, and obesity-related metabolic dysfunction. CRIOH partners with leading pharmaceutical organizations to ensure every study meets the highest scientific and ethical standards.
Liver Disease Clinical Trials
CRIOH offers comprehensive evaluations for patients with all forms of liver disease, including fatty liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, and alcohol-associated liver disease. Through advanced non-invasive testing such as FibroScan, we screen and stage liver disease to determine eligibility for ongoing studies.
- BIO89-100-131: NASH patients with F2–F3 fibrosis
- BIO89-100-132: Cirrhotic MASH
- AKERO 105: Non-cirrhotic NASH with fibrosis
- AKERO 106: Cirrhosis
- ALTUMMUNE: Alcohol-associated liver disease (ALD)
- Boehringer Ingelheim 1404-0044: NASH patients with F2–F3 fibrosis
- Boehringer Ingelheim 1404-0064: Cirrhosis
These studies explore therapies aimed at reducing liver fat, decreasing inflammation, slowing fibrosis progression, and improving long-term liver health
Obesity Trials
CRIOH is part of the team that conducts obesity and metabolic disorder trials that evaluate new medications and therapies designed to support weight loss, improve metabolic function, and reduce the risk of progression to liver disease. Because obesity is tightly linked with MASLD and MASH, many of our obesity trials also include components that assess liver fat, inflammation, and fibrosis.
In addition to obesity-focused studies, NASH and metabolic liver disease studies that overlap with obesity may be available for qualified patients, including:
- BIO89-100-131: NASH patients with F2–F3 fibrosis
- BIO89-100-132: Cirrhotic MASH
- AKERO 105: Non-cirrhotic NASH with fibrosis
- Akero 106: Cirrhotic NASH
- Boehringer Ingelheim 1404-0044: NASH patients with F2–F3 fibrosis
- Eli Lilly: NASH Patients with F2-F3 – NO BIOPSY REQUIRED
Clinical Trials in Westlake, Ohio
Our team of investigators and coordinators is committed to advancing patient care through high-quality research. Contact the Clinical Research Institute of Ohio today at (440) 363-4000 or schedule an appointment online to learn more about active liver disease and obesity trials at our Westlake location.
Free Liver Health Screening
CRIOH offers liver health screenings at no cost to qualified patients with Type 2 diabetes, obesity, or fatty liver complications. Learn more to get yours scheduled today!
